TrialJournal of immunology research2015

The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).

Peter H Schafer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.